HALO (Halozyme Therapeutics) Other Current Payables: $0 Mil (As of Mar. 2026)


HALO Halozyme Therapeutics Inc HALO
93 GF Score
Price $76.19
GF Value $91.15
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Other Current Payables?

Halozyme Therapeutics HALO -3.08% 93 Other Current Payables is $0 Mil as of Mar. 2026. GuruFocus rates HALO with a GF Score™ of 93/100 and a GF Value™ of $91.15 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Halozyme Therapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was $0 Mil.

Halozyme Therapeutics Other Current Payables Related Terms

Halozyme Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Other Current Payables Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Halozyme Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HALO
93GF Score
Halozyme Therapeutics Inc HALO
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0 Mil mean?
Halozyme Therapeutics (HALO) has a Other Current Payables of $0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Other Current Payables too high?
Halozyme Therapeutics' current Other Current Payables is $0 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Other Current Payables compare to KYMR and IBRX?
Halozyme Therapeutics' Other Current Payables of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Other Current Payables is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.15, compared to a current price of $76.19 — trading 16.4% below its estimated fair value. The current Other Current Payables is $0 Mil. Halozyme Therapeutics' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Other Current Payables is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of $76.19 is trading 16.4% below its estimated GF Value™ of $91.15. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for HALO:

  • Other Current Payables: $0 Mil
  • GF Value™: $91.15 vs. price of $76.19 (16.4% below fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
93GF Score

Get the complete analysis for HALO

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$76.19
Price
$91.15
GF Value